ArticleJournal of biomedical optics2025
"hDOS": an automated hybrid diffuse optical device for real-time noninvasive tissue monitoring: precision and
Article in Journal of biomedical optics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Significance: The hybrid diffuse optical system (hDOS) is a fully automated platform designed to bring advanced optical monitoring closer to clinical practice. Many existing systems lack automation, multiparametric output, and operator independence, limiting their use in demanding environments such as intensive care. hDOS integrates time-domain near-infrared spectroscopy, diffuse correlation spectroscopy, and pulse oximetry to assess both tissue oxygenation and perfusion. Although initially developed in the context of vascular occlusion tests, its modular design makes it suitable for broader applications, including trauma, surgery, anesthesia, and studies in healthy subjects. Aim: It aims to design and validate hDOS, focusing on precision, repeatability, and usability for peripheral microvascular monitoring in both clinical and research settings. Approach: Validation included test-retest measurements, a 7-month clinical deployment in the critical care, and a comparison with a commercial continuous wave NIRS device (INVOS 5100C). Results: The device underwent extensive validation, accumulating over 200 h of usage across Conclusions: hDOS performed well in both bench and clinical settings, offering a unique combination of parameters in a fully automated, self-contained platform.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.